Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.

Future oncology (London, England) - 1 Jan 2024

Muthusamy Bharathi, Berktas Mehmet, Li Jingyi, Thomas Darren S, Sun Ping, Taylor Aliki, Pennell Nathan A

Abstract excerpt

Aim: To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC).Methods: Electronic records of USA-based patients in the CancerLinQ Discovery® database with stage IA-IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis.Results: Of 3121 (21.6%) patients who had EGFR testing, 493...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Databases, Factual

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Source

Open in PubMed Open full text

Identifiers

PMID: 38916211
DOI: 10.1080/14796694.2024.2347826
PMCID: PMC11497985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.PMID 38916211Read ↗

EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.Semantic proximity Read ↗

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.Semantic proximity Read ↗

Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.Semantic proximity Read ↗

Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.Semantic proximity Read ↗

Evidence from resected early-stage non-small cell lung cancer with EGFR mutation: a literature review.Semantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.Semantic proximity Read ↗

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational StudySemantic proximity Read ↗

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.Semantic proximity Read ↗

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.Semantic proximity Read ↗

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinionSemantic proximity Read ↗

EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.